Yunming Mu

Abstract 526: RMC-9805, a first-in-class, mutant-selective, covalent and oral KRASG12D(ON) inhibitor that induces apoptosis and drives tumor regression in preclinical models of KRASG12D cancers

Lingyan Jiang, Marie Ménard, Caroline E. Weller et al. · Cancer Research · 2023 · 61 citations

Oral Krasg12d, Tumor Biology, Krasg12d Nsclc +13

Surgical Experience in Two Multicenter, Open-Label Phase 3 Studies of Emicizumab in Persons with Hemophilia A with Inhibitors (HAVEN 1 and HAVEN 2)

Rebecca Kruse‐Jarres, Michael U. Callaghan, Stacy E. Croteau et al. · Blood · 2017 · 50 citations

Abstract PR014: Preliminary safety and anti-tumor activity of RMC-6291, a first-in-class, tri-complex KRASG12C(ON) inhibitor, in patients with or without prior KRASG12C(OFF) inhibitor treatment

Pasi A. Jänne, Frédéric Bigot, Kyriakos P. Papadopoulos et al. · Molecular Cancer Therapeutics · 2023 · 50 citations

Preliminary Safety, Pharmacotherapy, Tumor Biology +18

Clinical and Economic Burden of Commercially Insured Patients with Acromegaly in the United States: A Retrospective Analysis

Hilary Placzek, Yaping Xu, Yunming Mu et al. · Journal of Managed Care & Specialty Pharmacy · 2015 · 31 citations · Full text

Abstract 3597: Direct targeting of KRASG12X mutant cancers with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RASMULTI(ON) inhibitor

Elena S. Koltun, Meghan A. Rice, W. Clay Gustafson et al. · Cancer Research · 2022 · 30 citations

Tri-complex Rasmulti, Cancer Biology, Tumor Biology +20